Clinical Trial Update: Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome [Phase 1]

View source ↗

Summary

Phase I trial evaluating recombinant human IL-15 in combination with mogamulizumab for refractory/relapsed adult T-cell leukemia/lymphoma and Sezary syndrome co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides
• Sezary Syndrome
• T-cell Leukemia Lymphoma

Drugs mentioned

• Mogamulizumab (mogamulizumab)
• recombinant human IL-15 (rhIL-15)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome | Phase 1 | Status: COMPLETED | Results posted: 2021-12-14